(Q45396442)

14 December 2017

0 references

1 reference

title

Epstein-Barr virus in the development of multiple sclerosis (English)

1 reference

14 December 2017

0 references

0 references

1

Alberto Ascherio

1 reference

14 December 2017

1 March 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 December 2017

1 reference

14 December 2017

8

1 reference

14 December 2017

3

1 reference

14 December 2017

331-333

1 reference

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

14 December 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Environmental risk factors for multiple sclerosis. Part I: The role of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Multiple sclerosis in the faroe islands: I. Clinical and epidemiological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

The effect of infections on susceptibility to autoimmune and allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Epstein-Barr virus and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Epstein-Barr virus in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

High seroprevalence of Epstein-Barr virus in children with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

A randomized clinical trial of valacyclovir in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

Multiple Sclerosis After Infectious Mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.3.331

21 January 2018

Identifiers

DOI

10.1586/14737175.8.3.331

1 reference

14 December 2017

1 reference

PubMed ID

18345964